Your browser doesn't support javascript.
loading
Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors.
Tani, Ryosuke; Matsunaga, Keiji; Toda, Yuta; Inoue, Tomoko; Fu, Hai Ying; Minamino, Tetsuo.
Afiliación
  • Tani R; Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Kagawa Japan.
  • Matsunaga K; Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Kagawa Japan.
  • Toda Y; Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Kagawa Japan.
  • Inoue T; Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Kagawa Japan.
  • Fu HY; Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Kagawa Japan.
  • Minamino T; Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine Kagawa University Kagawa Japan.
Clin Case Rep ; 12(2): e8537, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38380379
ABSTRACT
Recent data reveal phenotypic HoFH patients may be responsive to PCSK9 inhibitors, challenging prior assumptions. Genetic testing advancements now more accurately forecast patient responses to these therapies, improving treatment strategies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Case Rep Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Case Rep Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido